Status:
COMPLETED
Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Gram-Positive Bacterial Infections
Eligibility:
All Genders
18+ years
Brief Summary
To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a su...
Eligibility Criteria
Inclusion
- All patients admitted to or transferred to the SICU.
- Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU.
- Provide written informed consent
Exclusion
- Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase inhibitors.
- Females who are pregnant and breast feeding
- Any underlying conditions or non-infectious diseases that will be ultimately fatal within 48 hours.
- Those who have already been participating other clinical study related with antibiotics.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT00167960
Start Date
January 1 2005
Last Update
March 15 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Incheon, South Korea, 405-760
2
Ulsan, South Korea, 682-714